Aug 9, 2021

本文共1124个字，阅读需3分钟 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210809005608/en/S-Alpha Therapeutics raised a total of $8.7M USD (10 Billion KRW) in Series A financing round with the participation by existing investors and new Venture Capitalist (VC) funding.In 2020, S-Alpha Therapeutics raised $2.7M USD (3 Billion KRW) in seed round of funding from Hana Ventures, STIC Ventures, AJU IB Investment, SJ Investment Partners, and TONY Investment. In Series A funding, all existing investors participated in this investment, and Korea Investment Partners, Stonebridge Ventures, Devsisters Ventures/KDB Capital, and Timewise Investment participated as new investors.“The convergence of information technology (IT) and biotechnology is an inevitable industry trend. The investment in this industry is the driving force for fast product development, verification of new concepts and enhances the development of disruptive technologies. It also provides resources and infrastructure for validating the safety as well as efficacy of the product” said STIC Ventures, which led this investment.Dr. Yong-Sun Lee, Chief Strategy Officer from S-Alpha Therapeutics said “With this investment, we plan to develop and validate SAT-001, the leading product in pediatric myopia, through clinical trials in Korea and in US. S-Alpha Therapeutics will also use this fund to complete verification of SAT-008 and support R&D efforts to validate the concept in new disease areas of our pipeline.About S-Alpha Therapeutics, Inc.Founded in 2019, S-Alpha Therapeutics develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology. Company has developed several digital therapeutic products in its R&D pipeline.Currently, company is conducting clinical trials to evaluate the efficacy, safety and feasibility of SAT-001 in several clinical sites in South Korea.Among the company's pipelines, SAT-008, developed for the purpose of inducing an individual's immune-boosting effect, is in the process of establishing a business development model according to the evidence generated from clinical studies in South Korea. In addition, S-Alpha Therapeutics is in the process of developing other products in the pipeline.www.salphadtx.comView source version on businesswire.com: https://www.businesswire.com/news/home/20210809005608/en/For media contact: Sanghun Leeemail: sanghun@salphadtx.comPhone : 82-2-3487-3923Source: S-Alpha Therapeutics, Inc.View this news release online at:http://www.businesswire.com/news/home/20210809005608/en 本新闻稿以多媒体为特色。在这里查看完整版本:https://www.businesswire.com/news/home/20210809005608/en/在现有投资者和新的风险资本家(VC)的参与下，S-Alpha Therapeutics在a轮融资中总共筹集了870万美元（100亿韩元）。2020年，S-Alpha Therapeutics从Hana Ventures、STIC Ventures、AJU IB Investment、SJ Investment Partners和TONY Investment筹集了270万美元（30亿KRW）的种子轮资金。在A系列融资中，所有现有投资者都参与了这项投资，Korea investment Partners、Stonebridge Ventures、Devsisters Ventures/KDB Capital和Timewise investment作为新投资者参与。“信息技术(IT)与生物技术的融合是必然的产业趋势。对该行业的投资是快速产品开发、新概念验证和促进颠覆性技术发展的驱动力。它还为验证产品的安全性和有效性提供了资源和基础设施。S-Alpha Therapeutics的首席战略官李永善博士说：“通过这笔投资，我们计划在韩国和美国通过临床试验开发和验证儿童近视的领先产品SAT-001。S-Alpha治疗公司还将利用这笔资金来完成SAT-008的验证，并支持研发工作，以在我们管道中的新疾病领域验证这一概念。关于S-Alpha治疗公司。成立于2019年的S-Alpha Therapeutics开发数字治疗学，这是一种来自生物学和信息技术融合的治疗干预。公司已经开发了几个数字化治疗产品在其研发管道。目前，该公司正在韩国的几个临床点进行临床试验，以评估SAT-001的有效性、安全性和可行性。在该公司的管道中，为诱导个人免疫增强效应而开发的SAT-008正在根据韩国临床研究产生的证据建立业务发展模式。此外，S-Alpha疗法正在开发其他产品。www.salphadtx.com在businesswire.com查看源代码版本:https://www.businesswire.com/news/home/20210809005608/en/供媒体联系：Sanghun Lee电子邮件:sanghun@salphadtx.com电话：82-2-3487-3923资料来源：S-Alpha治疗公司。在网上查看此新闻稿：http://www.businesswire.com/news/home/20210809005608/en 以上中文文本为机器翻译，存在不同程度偏差和错误；偶尔因源网页结构局限，内容无法一次完整呈现。请理解并参考原站原文阅读。